The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Registration Number
- NCT04169828
- Lead Sponsor
- University of British Columbia
- Brief Summary
Far too many kids and families live in dread over the weekly nausea and vomiting caused by methotrexate - a medicine that controls joint swelling in Juvenile Arthritis patients. If methotrexate is not tolerated, expensive alternative biological medications may be started. This registry-based pragmatic randomized controlled trial will evaluate if routine premedication with the anti-emetic drug Ondansetron, reduces nausea and vomiting and increases the proportion of children able to continue methotrexate. By preventing nausea before it starts, the investigators hope to give kids and families a better quality of life and see a more cost-effective use of medication.
- Detailed Description
1. Purpose:
To evaluate if routine pre-medication with the anti-emetic ondansetron reduces methotrexate intolerance and increases the proportion of children with JIA able to continue taking methotrexate, resulting in a better quality of life and more cost-effective medication use.
2. Hypothesis:
Prophylactic prescription of ondansetron with methotrexate will increase the proportion of children that remain on methotrexate and intolerance free one year after starting methotrexate, relative to prescription of ondansetron after intolerance symptoms develop.
3. Justification:
Methotrexate intolerance is thought to be largely the result of Pavlovian conditioning secondary to previous exposure and symptoms can be triggered by associated stimuli, such as a yellow liquid similar in color to methotrexate or the smell of alcohol cleansing swabs. This intolerance leads to poor adherence to optimal dosing or to stopping the medication altogether. Children who cannot adhere to optimal dosing or stop methotrexate may require expensive biologic medications to control their JIA. Methotrexate intolerance often leads to use of anti-emetic medications which, unfortunately, rarely reverse conditioned responses. In oncology anti-emetics are used prophylactically as premedication in all subjects receiving chemotherapy to prevent the establishment of conditioned intolerance.
By conducting a registry-based pragmatic adaptive superiority randomized clinical trial the investigators will include most subjects in whom the treatment may be used under the usual conditions of practice to demonstrate effectiveness under real word circumstances. Patients enrolled in a pragmatic trial are more representative because eligibility criteria are less strict. More so, a registry-based pragmatic RCT can also be much cheaper than a traditional RCT.
4. Objectives:
The investigators will assign patients starting low-dose methotrexate for JIA 1:1 online using the CAPRI Registry and block randomization by Canadian region and patient weight to one of two groups:
Intervention: Routine premedication with oral ondansetron (2, 4 or 8 mg for patient weights \<15Kg, 15-30Kg, \>30 Kg; 3 doses a week).
Control: Oral ondansetron at the same dosing, prescribed only to those patients who develop methotrexate-induced nausea/vomiting during usual care.
The investigators will compare:
1. The proportions of patients remaining on methotrexate with no intolerance between the two groups one year after starting methotrexate (primary objective).
2. Safety and tolerability
3. The cumulative incidence of:
1. methotrexate intolerance
2. attainment of inactive disease
3. biologic medication initiation
4. The mean quality of life scores and methotrexate intolerance severity scores between the two groups 4-8 months after starting methotrexate.
The investigators will also collect information on impacts on quality of life and medication utilization that will enable a future cost-effectiveness analysis.
5. Research Design:
The investigators will conduct a CAPRI JIA Registry-based pragmatic adaptive superiority RCT as per the following methods.
Registry-based: The trial will use infrastructure already in place for the CAPRI JIA Registry.
Pragmatic: Broad inclusion criteria and simple outcome assessments compatible with usual care.
Adaptive: This is a Planned Sample-Size Re-Estimation Adaptive Trial as described by Bhatt \& Metha \[34\].
Superiority: Designed to test superiority (as opposed to non-inferiority) of ondansetron premedication.
RCT: Treatments assigned by block randomization and analyses adjusted for post-randomization imbalances
6. Statistical Analysis:
The primary outcome statistic is the ratio of two proportions (relative risk, RR), the proportion of children remaining on methotrexate with no intolerance in the intervention group divided by the same in the control group. This choice allows flexibility for the frequency of follow-up visits to be set-up as per clinical need, obviating the need for study-specific visits, increasing feasibility and decreasing costs. It is also not impacted by the times at which methotrexate intolerance or discontinuation occur which leads to simplicity in interpretation and analysis.
The sample size calculation is based on expressing the RR in the log scale and using established formulas for standard errors. With p\<0.05, power of 90% and expected methotrexate continuation with no intolerance of 50% in the control group and 75% in the intervention group the result is 79 evaluable subjects per group. The investigators will aim to recruit 176 subjects total to allow for up to a 10% dropout rate, although they expect a dropout rate of \<5% based on previous CAPRI studies.
A preliminary analysis after recruitment of 90 subjects will consist of a two-sided confidence interval (CI) for the RR of continuing on methotrexate with no intolerance, where the confidence level is adjusted for information accrual as per Schoenfeld.
The Data and Safety Committee will assess preliminary results according to the following guidance:
If the CI is entirely below a relative risk of 1.2, the study will be stopped for futility.
If the CI is entirely above a relative risk of 1.2, the study will be stopped and superiority will be claimed.
If the CI includes a relative risk of 1.2, the trial will continue until the re-calculated full target sample is attained.
The RR of 1.2 has been selected on clinical grounds. In a prospective study of 142 children with JIA starting methotrexate followed for one year, Van Dijkhuizen et al reported that 59 patients developed intolerance and 11 discontinued methotrexate for other reasons, for a total of 72 (50.7%) remaining on methotrexate with no intolerance. An increase in this proportion to \<60% is deemed too small to justify the additional costs and risks of adding prophylactic ondansetron.
The final analysis will be an intention to treat analysis conducted after the final sample size is achieved or at the time the study is stopped. All subjects enrolled in the study at that time will complete a one-year follow-up and will be included in the final analysis. Logistic regression models will be used to adjust effect estimates for post-randomization imbalances in the two groups (intervention, control). A secondary per-protocol analysis will be conducted on those subjects who received the assigned intervention for at least 3 months.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 52
- Ages 4-16 years
- Diagnosis of JIA as per ILAR criteria [1], irrespective of JIA category
- Followed at a CAPRI centre in Canada
- Starting methotrexate to control JIA manifestations (arthritis, uveitis, psoriasis). (Female subjects of child bearing potential who are taking methotrexate for JIA cannot be pregnant, breastfeeding, or planning a pregnancy while on the drug and females of childbearing potential who are sexually active must use highly effective medically acceptable contraception. Subjects who stop methotrexate during the study will also discontinue ondansetron.)
- Informed written consent to participate
- Participating in the CAPRI JIA Registry
-
Previous use of methotrexate
-
Known hypersensitivity to ondansetron or any components of its formulations
-
Known hypersensitivity to other 5-HT3 antagonists
-
Known congenital Long-QT syndrome
-
Patients taking other medicinal products that lead to either QT prolongation or electrolyte abnormalities
-
Because the serotonin syndrome may occur when ondansetron is combined with other agents that may affect the serotonergic neurotransmitter system, patients receiving any of the serotonergic and/or neuroleptic drugs listed below will be excluded:
• Triptans, SSRIs, SNRIs, lithium, sibutramine, fentanyl and its analogues, dextromethorphan, tramadol, tapendalol, meperidine, methadone, pentazocine or St. John's Wort (Hypericum perforatum), MAOIs, linezolid, methylene blue.
-
Patients who are pregnant or breastfeeding, or are sexually active and unwilling to practice an acceptable method of birth control.
-
Family unable to complete questionnaires in English or French
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Ondansetron as needed Folic/folinic acid Methotrexate and folic/folinic acid as prescribed by physician. ONLY children who report nausea/vomiting during regular care will be prescribed ondansetron at the same dose as in experimental group (2 mg if \<15Kg, 4 mg if 15-30Kg, 8 mg if \>30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake), as per the attending rheumatologist's discretion Ondansetron premedication Folic/folinic acid Methotrexate and folic/folinic acid as prescribed by physician. Ondansetron: 2 mg if \<15Kg, 4 mg if 15-30Kg, 8 mg if \>30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake. To be started from the very first dose of methotrexate. Ondansetron premedication Ondansetron Methotrexate and folic/folinic acid as prescribed by physician. Ondansetron: 2 mg if \<15Kg, 4 mg if 15-30Kg, 8 mg if \>30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake. To be started from the very first dose of methotrexate. Ondansetron premedication Methotrexate Methotrexate and folic/folinic acid as prescribed by physician. Ondansetron: 2 mg if \<15Kg, 4 mg if 15-30Kg, 8 mg if \>30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake. To be started from the very first dose of methotrexate. Ondansetron as needed Ondansetron Methotrexate and folic/folinic acid as prescribed by physician. ONLY children who report nausea/vomiting during regular care will be prescribed ondansetron at the same dose as in experimental group (2 mg if \<15Kg, 4 mg if 15-30Kg, 8 mg if \>30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake), as per the attending rheumatologist's discretion Ondansetron as needed Methotrexate Methotrexate and folic/folinic acid as prescribed by physician. ONLY children who report nausea/vomiting during regular care will be prescribed ondansetron at the same dose as in experimental group (2 mg if \<15Kg, 4 mg if 15-30Kg, 8 mg if \>30Kg to be taken by mouth one hour before each weekly methotrexate dose, followed by two additional doses every 6-8 hours if awake), as per the attending rheumatologist's discretion
- Primary Outcome Measures
Name Time Method Proportion of subjects that remain on methotrexate with no intolerance One year after starting methotrexate. Intolerance will be defined as ≥6 points in the English or French versions of the validated Methotrexate Intolerance Severity Score, MISS \[10, 36\]. Scores in the MISS questionaire go from 0 (no signs of intolerance) to a maximum of 36 (all signs of intolerance are severe). The MISS questionnaire takes less than 2 minutes to complete (see Appendix). It will be added to the Registry questionnaires completed by families online or on paper as per the CAPRI Centre usual Registry procedures.
- Secondary Outcome Measures
Name Time Method Frequency and cumulative incidence of adverse events (safety and tolerability) Within one year Frequency and cumulative incidence of adverse events, and any suspected unexpected serious adverse drug reactions (SUSARs).
Methotrexate intolerance Within one year The cumulative incidence of methotrexate intolerance
Attainment of inactive disease Within one year The cumulative incidence of attainment of inactive disease, defined by Wallace criteria
Starting a biologic medication Within one year The cumulative incidence of starting a biologic medication
Quality of My Life scale 4-8 months after starting methotrexate Mean quality of life scores in the Quality of My Life scale. The scale has a minimum value of zero (WORST quality of life) and a maximum value of 10 (BEST quality of life).
MISS questionnaire 4-8 months after starting methotrexate Mean scores in the Methotrexate Intolerance Severity Score (MISS) questionnaire. Scores in the MISS questionnaire go from 0 (no signs of intolerance) to a maximum of 36 (all signs of intolerance are severe).
Trial Locations
- Locations (11)
University of Calgary / Alberta Children's Hospital
🇨🇦Calgary, Alberta, Canada
BC Children's Hospital
🇨🇦Vancouver, British Columbia, Canada
University of Alberta
🇨🇦Edmonton, Alberta, Canada
University of Manitoba/Children's hospital research institute
🇨🇦Winnipeg, Manitoba, Canada
Hospital for Sick Children
🇨🇦Toronto, Ontario, Canada
London Health Sciences Centre
🇨🇦London, Ontario, Canada
CHU de Quebec - Universite Laval
🇨🇦Québec, Quebec, Canada
Royal University Hospital
🇨🇦Saskatoon, Saskatchewan, Canada
McGill University Health Centre
🇨🇦Montréal, Quebec, Canada
McMaster University/McMaster Children's Hospital
🇨🇦Hamilton, Ontario, Canada
Université de Montréal
🇨🇦Montréal, Quebec, Canada